Dr. Ignacio Muñoz-Sanjuán began his research training in molecular and developmental genetics at Johns Hopkins University in the mid-1990s. After a postdoctoral fellowship at the Rockefeller, he moved to industry, working in the neuroscience units of Merck Sharp & Dohme and, later, Amgen. In late 2007 he joined CHDI Foundation, a private non-profit organization with the ‘simple’ mission of supporting drug-discovery research to slow the progression of Huntington’s disease (HD). CHDI funds dozens of academic research labs, collaborates with many industry and other partners worldwide, and coordinates with NIH. As VP of Translational Biology, Dr. Muñoz-Sanjuán oversees a large portfolio focused on two major goals. The first is based on molecular strategies to lower levels of the toxic form of HTT which causes HD-type neurodegeneration. The second is based on neurophysiological methods to normalize brain circuitry for symptomatic relief. Dr. Muñoz-Sanjuán also founded Factor-H, a non-profit NGO that supports families in Latin America impacted by HD.